228 related articles for article (PubMed ID: 30861284)
1. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia.
Fidyt K; Pastorczak A; Goral A; Szczygiel K; Fendler W; Muchowicz A; Bartlomiejczyk MA; Madzio J; Cyran J; Graczyk-Jarzynka A; Jansen E; Patkowska E; Lech-Maranda E; Pal D; Blair H; Burdzinska A; Pedzisz P; Glodkowska-Mrowka E; Demkow U; Gawle-Krawczyk K; Matysiak M; Winiarska M; Juszczynski P; Mlynarski W; Heidenreich O; Golab J; Firczuk M
Mol Oncol; 2019 May; 13(5):1180-1195. PubMed ID: 30861284
[TBL] [Abstract][Full Text] [Related]
2. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells.
Accordi B; Galla L; Milani G; Curtarello M; Serafin V; Lissandron V; Viola G; te Kronnie G; De Maria R; Petricoin EF; Liotta LA; Indraccolo S; Basso G
Leukemia; 2013 Apr; 27(5):1019-27. PubMed ID: 23228943
[TBL] [Abstract][Full Text] [Related]
3. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
[TBL] [Abstract][Full Text] [Related]
4. Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system.
Rajakumar SA; Grandal I; Minden MD; Hitzler JK; Guidos CJ; Danska JS
Cell Rep Med; 2021 Dec; 2(12):100470. PubMed ID: 35028611
[TBL] [Abstract][Full Text] [Related]
5. MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL.
Yang W; Tran P; Khan Z; Rezk S; O'Brien S
Leuk Lymphoma; 2017 Jun; 58(6):1498-1501. PubMed ID: 27774846
[No Abstract] [Full Text] [Related]
6. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
7. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia.
Tejedor JR; Bueno C; Vinyoles M; Petazzi P; Agraz-Doblas A; Cobo I; Torres-Ruiz R; Bayón GF; Pérez RF; López-Tamargo S; Gutierrez-Agüera F; Santamarina-Ojeda P; Ramírez-Orellana M; Bardini M; Cazzaniga G; Ballerini P; Schneider P; Stam RW; Varela I; Fraga MF; Fernández AF; Menéndez P
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983906
[TBL] [Abstract][Full Text] [Related]
8. High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Bakker M; Hoogkamer AQ; Boer JM; Hartman QJ; Stalpers F; Escherich G; de Haas V; de Groot-Kruseman HA; Pieters R; den Boer ML
Sci Rep; 2018 Jan; 8(1):693. PubMed ID: 29330417
[TBL] [Abstract][Full Text] [Related]
9. Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia.
Oliveira T; Zhang M; Joo EJ; Abdel-Azim H; Chen CW; Yang L; Chou CH; Qin X; Chen J; Alagesan K; Almeida A; Jacob F; Packer NH; von Itzstein M; Heisterkamp N; Kolarich D
Theranostics; 2021; 11(19):9519-9537. PubMed ID: 34646384
[TBL] [Abstract][Full Text] [Related]
10. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
11. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
[TBL] [Abstract][Full Text] [Related]
12. Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.
Fidyt K; Pastorczak A; Cyran J; Crump NT; Goral A; Madzio J; Muchowicz A; Poprzeczko M; Domka K; Komorowski L; Winiarska M; Harman JR; Siudakowska K; Graczyk-Jarzynka A; Patkowska E; Lech-Maranda E; Mlynarski W; Golab J; Milne TA; Firczuk M
Oncogene; 2022 Mar; 41(11):1600-1609. PubMed ID: 35091682
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
[No Abstract] [Full Text] [Related]
15. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements.
Roolf C; Richter A; Konkolefski C; Knuebel G; Sekora A; Krohn S; Stenzel J; Krause BJ; Vollmar B; Murua Escobar H; Junghanss C
J Hematol Oncol; 2018 May; 11(1):62. PubMed ID: 29728108
[TBL] [Abstract][Full Text] [Related]
16. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group.
Burmeister T; Meyer C; Schwartz S; Hofmann J; Molkentin M; Kowarz E; Schneider B; Raff T; Reinhardt R; Gökbuget N; Hoelzer D; Thiel E; Marschalek R
Blood; 2009 Apr; 113(17):4011-5. PubMed ID: 19144982
[TBL] [Abstract][Full Text] [Related]
17. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
Benito JM; Godfrey L; Kojima K; Hogdal L; Wunderlich M; Geng H; Marzo I; Harutyunyan KG; Golfman L; North P; Kerry J; Ballabio E; Chonghaile TN; Gonzalo O; Qiu Y; Jeremias I; Debose L; O'Brien E; Ma H; Zhou P; Jacamo R; Park E; Coombes KR; Zhang N; Thomas DA; O'Brien S; Kantarjian HM; Leverson JD; Kornblau SM; Andreeff M; Müschen M; Zweidler-McKay PA; Mulloy JC; Letai A; Milne TA; Konopleva M
Cell Rep; 2015 Dec; 13(12):2715-27. PubMed ID: 26711339
[TBL] [Abstract][Full Text] [Related]
18. Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants.
Fazio G; Bardini M; De Lorenzo P; Grioni A; Quadri M; Pedace L; Corral Abascal L; Palamini S; Palmi C; Buldini B; Vinti L; Parasole R; Barisone E; Zecca M; Favre C; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Biondi A; Cazzaniga G
Blood; 2021 Apr; 137(14):1980-1984. PubMed ID: 33512459
[No Abstract] [Full Text] [Related]
19. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
20. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.
Lin S; Luo RT; Ptasinska A; Kerry J; Assi SA; Wunderlich M; Imamura T; Kaberlein JJ; Rayes A; Althoff MJ; Anastasi J; O'Brien MM; Meetei AR; Milne TA; Bonifer C; Mulloy JC; Thirman MJ
Cancer Cell; 2016 Nov; 30(5):737-749. PubMed ID: 27846391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
